We hypothesized that CCND1 and CCNE1 activation could represent a mechanism for palbociclib resistance in HNSCC, considering recent clinical data showing high CCNE1 as worse clinical outcome for palbociclib-treated patients in breast cancer (33, 34). The gene discussed is CCND1; the disease is head and neck squamous cell carcinoma.